Clinical Trial Search

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Antibiotic Sparing — 89; 121 Participants — p=0.025

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants

Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Number of Patients With Adverse Events (AEs) — 27 participants

Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04

Primary: Percentage of Subjects With Clinically Symptomatic Respiratory Illness — 125; 134 Participants

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72

Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460

Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits

Primary: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4 — 12.96; 12.87; 12.71 units on a scale

Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale

Primary: Number of Participants With Adverse Events — 10; 4; 6; 10 Participants — p=0.05

Primary: Trough FEV1 After 12 Weeks on Study Drug — 0.0378; 0.0947 Litre — p=0.3025

Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001

Primary: Compliance (Was the Dosage Followed - Yes, no) — 3154; 12; 15; 2 Participants

Primary: Body Temperature — 183; 170; 13; 2617 Participants